Miller & Martin Represents Mayne Pharma in Transactions with HedgePath Pharmaceuticals, Inc.
July 01, 2014
Miller & Martin attorneys represented Mayne Pharma in the out-licensing of its SUBA™-Itraconazole intellectual property to U.S.-based HedgePath Pharmaceuticals, Inc. (HPPI). SUBA™-Itraconazole is Mayne Pharma's patented oral formulation of itraconazole, which HPPI plans to develop for the treatment of a variety of cancers in the United States. As part of the transaction, Mayne Pharma has acquired an equity stake of approximately 40% in HPPI in return for granting HPPI an exclusive right to SUBA™-Itraconazole for anti-cancer applications in the US. Additionally, Mayne Pharma will supply HPPI with SUBA™-Itraconazole for use in clinical trials and for exclusive commercial supply following FDA approval.
Mayne Pharma is a specialty pharmaceutical company that develops and manufactures branded and generic products. Mayne Pharma distributes these products globally and operates two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, North Carolina, USA.
The Miller & Martin team representing Mayne Pharma included Joe DeLisle, Kent Antley, Jimmy Daniel, Bill DuPre, Billy Eiselstein, Jonathan Edwards, Charles Forlidas, Ashley Halfman, Chris Henderson, Mike Marshall, Tim Silvis, Jim Tramonte, Clay Walts and Frank Williams.
To read more, please click here.